MGC Pharmaceuticals Ltd. announced that the Israeli Ministry of Health has approved the Dosing Study for CimetrATM, MGC Pharma's proprietary treatment for the effects of COVID-19. The Study will incorporate key parameters including determining the most effective dosage of the treatment, a full safety and Pharmacovigilance profile, in addition to an extensive Pharmacokinetic profile to outline the registration and administrative process of approval for sale and use. The study will further examine the anti-inflammatory and immune-modulatory effects of CimetrATM through Cytokine level monitoring. MGC Pharma will recruit 240 patients into the Study in sites located in Israel, South Africa, the USA, and Russia, and will continue to observe patients enrolled in the trial for the 28 day follow up period in order to ensure that data is not impacted by the effects of either long or post-COVID. The results will be submitted to the health authorities of Israel, the USA, South Africa, and Russia. The results of this dosing study will enable MGC Pharma to determine the most effective dosage of CimetrATM for treating the symptoms of COVID-19 including the Cytokine Storm. The results of this Study will be used to provide additional evidence to regualtory authorities around the world about CimetrATM's efficacy.